We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Research highlights treatment response variability in Plasmodium vivax recurrence with Primaquine, suggesting CYP2D6 role in some patients.
variability influences treatment response, particularly in intermediate/poor metabolizers.
No takes yet. Share an insight, caveat, or question.
Godinho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: